| Market Capitalization (Millions $) |
- |
| Shares
Outstanding (Millions) |
225 |
| Employees |
- |
| Revenues (TTM) (Millions $) |
20 |
| Net Income (TTM) (Millions $) |
-354 |
| Cash Flow (TTM) (Millions $) |
309 |
| Capital Exp. (TTM) (Millions $) |
7 |
Business Description
Immunomedics Inc is a biopharmaceutical company focused on developing innovative antibody-based therapies for the treatment of cancer. The company specializes in the research, development, and commercialization of antibody-drug conjugates (ADCs), which are designed to specifically target and kill cancer cells while minimizing harm to healthy cells.
One of Immunomedics' most important achievements is the development of Sacituzumab Govitecan, an ADC that has shown promising results in the treatment of various types of cancer, including metastatic triple-negative breast cancer. The company has also developed other ADC candidates targeting different cancer types and continues to advance its research in this field.
Immunomedics has established collaborations and partnerships with leading pharmaceutical companies to help expedite the development and commercialization of its products. The company has a strong pipeline of potential therapies under investigation, with a focus on advancing ADC technology and expanding into other cancer indications.
Overall, Immunomedics Inc's mission is to provide innovative and effective treatment options for cancer patients, with a particular emphasis on leveraging antibody-based therapies to improve outcomes and quality of life.
Company Address: 300 The American Road Morris Plains 7950 NJ
Company Phone Number: 605-8200 Stock Exchange / Ticker: NASDAQ IMMU
|
%